You are here

Samsung Bioepis seeks Europe's nod for its Humira drug copy

Wednesday, July 20, 2016 - 05:50

Samsung hopes its biosimilar company can emerge as a new growth driver.


BIOSIMILARS maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group, said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira.

Samsung Bioepis said that the European Medicines

Market voices on:

Pair your daily business read with the perfect cup of espresso.

Subscribe to The Business Times today to receive your very own Nespresso Inissia coffee machine worth $188.

Find out more at

Powered by GET.comGetCom